Elliptic Laboratories (Norway) Performance
| ELABS Stock | NOK 9.47 0.33 3.37% |
The firm shows a Beta (market volatility) of -0.17, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Elliptic Laboratories are expected to decrease at a much lower rate. During the bear market, Elliptic Laboratories is likely to outperform the market. At this point, Elliptic Laboratories has a negative expected return of -0.42%. Please make sure to confirm Elliptic Laboratories' value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Elliptic Laboratories performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Elliptic Laboratories AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 99.7 M | |
| Total Cashflows From Investing Activities | -17.6 M |
Elliptic |
Elliptic Laboratories Relative Risk vs. Return Landscape
If you would invest 1,290 in Elliptic Laboratories AS on August 30, 2024 and sell it today you would lose (343.00) from holding Elliptic Laboratories AS or give up 26.59% of portfolio value over 90 days. Elliptic Laboratories AS is generating negative expected returns and assumes 3.5269% volatility on return distribution over the 90 days horizon. Simply put, 31% of stocks are less volatile than Elliptic, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Elliptic Laboratories Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elliptic Laboratories' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Elliptic Laboratories AS, and traders can use it to determine the average amount a Elliptic Laboratories' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1199
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ELABS |
Estimated Market Risk
| 3.53 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Elliptic Laboratories is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Elliptic Laboratories by adding Elliptic Laboratories to a well-diversified portfolio.
Elliptic Laboratories Fundamentals Growth
Elliptic Stock prices reflect investors' perceptions of the future prospects and financial health of Elliptic Laboratories, and Elliptic Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Elliptic Stock performance.
| Return On Equity | -0.0289 | |||
| Return On Asset | -0.0328 | |||
| Profit Margin | (0.12) % | |||
| Operating Margin | (0.24) % | |||
| Current Valuation | 2 B | |||
| Shares Outstanding | 104.07 M | |||
| Price To Book | 6.39 X | |||
| Price To Sales | 27.21 X | |||
| Revenue | 54.6 M | |||
| EBITDA | (3.58 M) | |||
| Cash And Equivalents | 216.83 M | |||
| Cash Per Share | 9.94 X | |||
| Total Debt | 10.53 M | |||
| Debt To Equity | 0.12 % | |||
| Book Value Per Share | 3.29 X | |||
| Cash Flow From Operations | (10.82 M) | |||
| Earnings Per Share | (0.17) X | |||
| Total Asset | 371.36 M | |||
About Elliptic Laboratories Performance
By examining Elliptic Laboratories' fundamental ratios, stakeholders can obtain critical insights into Elliptic Laboratories' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Elliptic Laboratories is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Elliptic Laboratories AS provides software-based artificial intelligence virtual smart sensors in Norway, China, South Korea, the United States, and Japan. The company was founded in 2006 and is based in Oslo, Norway. ELLIPTIC LABORATOR is traded on Oslo Stock Exchange in Norway.Things to note about Elliptic Laboratories performance evaluation
Checking the ongoing alerts about Elliptic Laboratories for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Elliptic Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Elliptic Laboratories generated a negative expected return over the last 90 days | |
| Elliptic Laboratories has high historical volatility and very poor performance | |
| Elliptic Laboratories has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 54.6 M. Net Loss for the year was (13.09 M) with profit before overhead, payroll, taxes, and interest of 3.79 M. | |
| Elliptic Laboratories AS has accumulated about 216.83 M in cash with (10.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 31.0% of the company shares are held by company insiders |
- Analyzing Elliptic Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Elliptic Laboratories' stock is overvalued or undervalued compared to its peers.
- Examining Elliptic Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Elliptic Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Elliptic Laboratories' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Elliptic Laboratories' stock. These opinions can provide insight into Elliptic Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Elliptic Stock
Elliptic Laboratories financial ratios help investors to determine whether Elliptic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elliptic with respect to the benefits of owning Elliptic Laboratories security.